In a recent announcement, ZYLOXTB (02190) has been recognized as the 'Most Honored Company' in the 16th Asia's Best Managed Teams ranking (excluding Japan, Australia, and New Zealand) published by Extel. This accolade reflects the international investment community and analysts' endorsement of the company's management team, corporate governance, and investor relations efforts.
In this same ranking, ZYLOXTB also received recognition across multiple categories within the Healthcare Equipment & Services industry. These include 'Best CEO', 'Best CFO', 'Best IR Program', 'Best IR Team', and 'Best IR Professional'.
Extel, formerly known as Institutional Investor Research, is an independent research and ranking organization with long-standing credibility in global capital markets. Its Asia's Best Managed Teams ranking is determined through votes from global investors, fund managers, and analysts, focusing on dimensions such as listed companies' management teams, investor relations, corporate governance, ESG performance, and board effectiveness.
According to data released by Extel, the 2026 Asia's Best Managed Teams survey involved 5,581 investors, fund managers, and analysts from 1,249 voting institutions. It covered 2,520 companies and 2,728 individuals across 23 industries.
The recognition of ZYLOXTB as a 'Most Honored Company' and its high rankings in multiple categories demonstrate the international capital market's approval of the company's management capabilities, governance standards, transparency in information disclosure, and the quality of its investor communications. It also reflects the outcomes of the company's long-term commitment to standardized governance and steady development.
Dr. Zhong Zhao, Chairman and CEO of ZYLOXTB, stated, "We are honored to receive this recognition from Extel and the international investor and analyst community. This honor affirms the capital market's confidence in our corporate governance and management team, and it will motivate us to continue focusing on long-term value creation while persistently enhancing our investor relations management. Moving forward, the company will continue to deepen its innovation-driven and internationalization strategies, advance product R&D, commercialization capabilities, and global market expansion. We aim to make more high-quality and affordable innovative vascular intervention solutions accessible to patients worldwide, thereby continuously enhancing the company's long-term value."